Home
AI Agent
Annotations
Files

Pricing and plans
Get the full experience
We save the real magic for signed-in users.

Home Stock Screener Document Search Charting Watchlists Recent Filings

Tenax Therapeutics, Inc.(TENX US)

$1.62+0.010.62%Ext:$1.65+0.031.85%(Market Closed · 00:55:39 UTC)

Doc Search Profile Entity StructureFinancials Charting Short Interest Employees

Overview

Profile Entity Structure

Documents

Categorized Chronological By Owner

Financials & Metrics

Financials Charting Short Interest Employees

Home
AI Agent
Annotations
Files

Pricing and plans
Get the full experience
We save the real magic for signed-in users.

Home Stock Screener Document Search Charting Watchlists Recent Filings

Tenax Therapeutics, Inc.(TENX US)

$1.62+0.010.62%Ext:$1.65+0.031.85%(Market Closed · 00:55:39 UTC)

Doc Search Profile Entity StructureFinancials Charting Short Interest Employees

Overview

Profile Entity Structure

Documents

Categorized Chronological By Owner

Financials & Metrics

Financials Charting Short Interest Employees

TENX US

TENX US

SEC Filings

SEC Filings

Financials(145)

10-QQ3ended 30 Sept 20265 Nov
10-QQ2ended 30 Jun 202631 Jul
10-QQ1ended 31 Mar 202612 May
10-KFY 2025ended 31 Dec 202510 Mar
10-QQ3ended 30 Sept 202512 Nov 2025
10-QQ2ended 30 Jun 202513 Aug 2025
10-QQ1ended 31 Mar 202514 May 2025
10-KFY 2024ended 31 Dec 202425 Mar 2025
10-QQ3ended 30 Sept 202413 Nov 2024
10-QQ2ended 30 Jun 202413 Aug 2024
10-QQ1ended 31 Mar 202414 May 2024
10-KFY 2023ended 31 Dec 202328 Mar 2024
10-QQ3ended 30 Sept 202313 Nov 2023
10-QQ2ended 30 Jun 202314 Aug 2023
10-QQ1ended 31 Mar 202315 May 2023

Events(217)

8-KTenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update5 Nov
8-KOther Events8 Oct
8-KRegulation FD Disclosure9 Sep
8-KTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial ofTNX-103in Patients withPH-HFpEF10 Aug
8-KTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update31 Jul
8-KTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 20262 Jul
8-KEntry into a Material Definitive Agreement30 Jun
8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers29 Jun
8-KSubmission of Matters to a Vote of Security Holders4 Jun
8-KTenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update12 May
8-KTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer22 Apr
8-KPRESS RELEASE10 Mar
8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers9 Jan
8-KPRESS RELEASE17 Dec 2025
8-KPRESS RELEASE12 Nov 2025

Insider Ownership(206)

Form 4ADAR1 Capital Management, LLC21 Oct
Form 4Doogan Declan17 Sep
Form 4Giordano Christopher Thomas15 Sep
Form 4STAAB THOMAS R II15 Sep
Form 4Schneeberger Daniel8 Sep
Form 4Schneeberger Daniel2 Sep
Form 4ADAR1 Capital Management, LLC24 Aug
Form 3ADAR1 Capital Management, LLC24 Aug
Form 4Giordano Christopher Thomas14 Jul
Form 4STAAB THOMAS R II13 May
Form 3STAAB THOMAS R II13 May
Form 4MCGAULEY THOMAS3 Feb
Form 4Davidson Michael H.13 Jan
Form 4Giordano Christopher Thomas13 Jan
Form 4Rich Stuart13 Jan

Beneficial Ownership(137)

SC 13G/ATENAX THERAPEUTICS, INC.12 Nov
SC 13G/ATENAX THERAPEUTICS, INC.27 Oct
SC 13G/ATENAX THERAPEUTICS, INC.15 Oct
SC 13G/ATENAX THERAPEUTICS, INC.13 Oct
SC 13G/ATENAX THERAPEUTICS, INC.9 Oct
SC 13G/ATENAX THERAPEUTICS, INC.11 Sep
SC 13GTENAX THERAPEUTICS, INC.8 Sep
SC 13G/ATENAX THERAPEUTICS, INC.8 Sep
SC 13GTENAX THERAPEUTICS, INC.27 Aug
SC 13GTENAX THERAPEUTICS, INC.27 Aug
SC 13GTENAX THERAPEUTICS, INC.18 Aug
SC 13G/ATENAX THERAPEUTICS, INC.14 Aug
SC 13G/ATENAX THERAPEUTICS, INC.14 Aug
SC 13G/ATENAX THERAPEUTICS, INC.14 Aug
SC 13G/ATENAX THERAPEUTICS, INC.14 Aug

Proxies(48)

ARSAnnual report to security holders22 Apr
DEFA14ADefinitive additional materials22 Apr
DEF 14ADefinitive proxy statement22 Apr
DEFA14ADefinitive additional materials25 Apr 2025
DEF 14ADefinitive proxy statement25 Apr 2025
ARSAnnual report to security holders25 Apr 2025
PRE 14APreliminary proxy statement9 Apr 2025
DEF 14ADefinitive proxy statement27 Sep 2024
DEFA14ADefinitive additional materials24 May 2024
ARSAnnual report to security holders26 Apr 2024
DEFA14ADEFA 14A26 Apr 2024
DEF 14ADefinitive proxy statement26 Apr 2024
DEFA14ADEFA 14A27 Oct 2023
DEF 14ADefinitive proxy statement27 Oct 2023
PRE 14APreliminary proxy statement16 Oct 2023

Registrations(144)

S-8Registration statement (employee benefit plan)12 May
S-3Registration statement (primary offering)24 Mar
424B3Prospectus filing (Rule 424(b)(3))23 Apr 2025
S-3Registration statement (primary offering)15 Apr 2025
424B3Prospectus filing (Rule 424(b)(3))12 Sep 2024
S-8Registration statement (employee benefit plan)30 Aug 2024
S-3Registration statement (primary offering)30 Aug 2024
POS AMPost-effective amendment (unspecified)11 Apr 2024
POS AMPost-effective amendment (unspecified)11 Apr 2024
424B3Prospectus filing (Rule 424(b)(3))26 Feb 2024
424B3Prospectus filing (Rule 424(b)(3))26 Feb 2024
424B3Prospectus filing (Rule 424(b)(3))21 Feb 2024
424B3B24B321 Feb 2024
424B3Prospectus filing (Rule 424(b)(3))13 Feb 2024
424B4Prospectus filing (Rule 424(b)(4))9 Feb 2024

Filing Review Correspondence(21)

CORRESPFiling review correspondence31 Mar
CORRESPFiling review correspondence21 Apr 2025
CORRESPFiling review correspondence10 Sep 2024
CORRESPFiling review correspondence5 Feb 2024
CORRESPFiling review correspondence5 Feb 2024
CORRESPFiling review correspondence1 Feb 2024
CORRESPFiling review correspondence10 Aug 2023
CORRESPFiling review correspondence1 Feb 2023
CORRESPFiling review correspondence1 Jun 2022
CORRESPFiling review correspondence31 Aug 2021
CORRESPFiling review correspondence29 Sep 2020
CORRESPFiling review correspondence11 Sep 2020
CORRESPFiling review correspondence7 Dec 2018
CORRESPFiling review correspondence7 Dec 2018
CORRESPFiling review correspondence6 Dec 2018

SEC Orders And Notices(22)

EFFECTNotice of effectiveness2 Apr
EFFECTNotice of effectiveness23 Apr 2025
EFFECTNotice of effectiveness12 Sep 2024
EFFECTNotice of effectiveness12 Apr 2024
EFFECTNotice of effectiveness12 Apr 2024
EFFECTNotice of effectiveness7 Feb 2024
EFFECTNotice of effectiveness2 Feb 2023
EFFECTNotice of effectiveness3 Jun 2022
EFFECTNotice of effectiveness1 Sep 2021
EFFECTNotice of effectiveness30 Sep 2020
EFFECTNotice of effectiveness7 Dec 2018
EFFECTNotice of effectiveness23 May 2018
EFFECTNotice of effectiveness6 Mar 2015
EFFECTNotice of effectiveness8 Sep 2014
EFFECTNotice of effectiveness13 Jun 2014

Exempt Offerings(11)

D06b23 Aug 2024
D06b1 Jun 2022
D06b20 Jul 2021
D06b22 Jul 2020
D06b27 Mar 2020
D06b29 Nov 2013
DNotice of exempt offering of securities (Reg D)3 Sep 2013
DNotice of exempt offering of securities (Reg D)7 Aug 2013
DNotice of exempt offering of securities (Reg D)8 Mar 2013
DNotice of exempt offering of securities (Reg D)22 Jun 2009
DNotice of exempt offering of securities (Reg D)10 Jun 2009

Other(11)

SEC STAFF LETTERSEC STAFF LETTER29 Mar 2021
SEC STAFF LETTERSEC STAFF LETTER1 Mar 2021
CERTNASAUTO-GENERATED PAPER DOCUMENT13 Jan 2010
S-2S-215 Aug 2005
S-2S-214 Jan 2005
S-2S-22 Sep 2004
10-K405FORM 10-K FOR PERIOD ENDED 4/30/20003 Aug 2000
10-K40510-K4051 Sep 1999
10-K40510-K40529 Jul 1998
10-K40510-K40529 Jul 1997
10-K40510-K4052 Aug 1996

Financials(145)

10-QQ3ended 30 Sept 20265 Nov
10-QQ2ended 30 Jun 202631 Jul
10-QQ1ended 31 Mar 202612 May
10-KFY 2025ended 31 Dec 202510 Mar
10-QQ3ended 30 Sept 202512 Nov 2025
10-QQ2ended 30 Jun 202513 Aug 2025
10-QQ1ended 31 Mar 202514 May 2025
10-KFY 2024ended 31 Dec 202425 Mar 2025
10-QQ3ended 30 Sept 202413 Nov 2024
10-QQ2ended 30 Jun 202413 Aug 2024
10-QQ1ended 31 Mar 202414 May 2024
10-KFY 2023ended 31 Dec 202328 Mar 2024
10-QQ3ended 30 Sept 202313 Nov 2023
10-QQ2ended 30 Jun 202314 Aug 2023
10-QQ1ended 31 Mar 202315 May 2023

Events(217)

8-KTenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update5 Nov
8-KOther Events8 Oct
8-KRegulation FD Disclosure9 Sep
8-KTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial ofTNX-103in Patients withPH-HFpEF10 Aug
8-KTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update31 Jul
8-KTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 20262 Jul
8-KEntry into a Material Definitive Agreement30 Jun
8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers29 Jun
8-KSubmission of Matters to a Vote of Security Holders4 Jun
8-KTenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update12 May
8-KTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer22 Apr
8-KPRESS RELEASE10 Mar
8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers9 Jan
8-KPRESS RELEASE17 Dec 2025
8-KPRESS RELEASE12 Nov 2025

Insider Ownership(206)

Form 4ADAR1 Capital Management, LLC21 Oct
Form 4Doogan Declan17 Sep
Form 4Giordano Christopher Thomas15 Sep
Form 4STAAB THOMAS R II15 Sep
Form 4Schneeberger Daniel8 Sep
Form 4Schneeberger Daniel2 Sep
Form 4ADAR1 Capital Management, LLC24 Aug
Form 3ADAR1 Capital Management, LLC24 Aug
Form 4Giordano Christopher Thomas14 Jul
Form 4STAAB THOMAS R II13 May
Form 3STAAB THOMAS R II13 May
Form 4MCGAULEY THOMAS3 Feb
Form 4Davidson Michael H.13 Jan
Form 4Giordano Christopher Thomas13 Jan
Form 4Rich Stuart13 Jan

Beneficial Ownership(137)

SC 13G/ATENAX THERAPEUTICS, INC.12 Nov
SC 13G/ATENAX THERAPEUTICS, INC.27 Oct
SC 13G/ATENAX THERAPEUTICS, INC.15 Oct
SC 13G/ATENAX THERAPEUTICS, INC.13 Oct
SC 13G/ATENAX THERAPEUTICS, INC.9 Oct
SC 13G/ATENAX THERAPEUTICS, INC.11 Sep
SC 13GTENAX THERAPEUTICS, INC.8 Sep
SC 13G/ATENAX THERAPEUTICS, INC.8 Sep
SC 13GTENAX THERAPEUTICS, INC.27 Aug
SC 13GTENAX THERAPEUTICS, INC.27 Aug
SC 13GTENAX THERAPEUTICS, INC.18 Aug
SC 13G/ATENAX THERAPEUTICS, INC.14 Aug
SC 13G/ATENAX THERAPEUTICS, INC.14 Aug
SC 13G/ATENAX THERAPEUTICS, INC.14 Aug
SC 13G/ATENAX THERAPEUTICS, INC.14 Aug

Proxies(48)

ARSAnnual report to security holders22 Apr
DEFA14ADefinitive additional materials22 Apr
DEF 14ADefinitive proxy statement22 Apr
DEFA14ADefinitive additional materials25 Apr 2025
DEF 14ADefinitive proxy statement25 Apr 2025
ARSAnnual report to security holders25 Apr 2025
PRE 14APreliminary proxy statement9 Apr 2025
DEF 14ADefinitive proxy statement27 Sep 2024
DEFA14ADefinitive additional materials24 May 2024
ARSAnnual report to security holders26 Apr 2024
DEFA14ADEFA 14A26 Apr 2024
DEF 14ADefinitive proxy statement26 Apr 2024
DEFA14ADEFA 14A27 Oct 2023
DEF 14ADefinitive proxy statement27 Oct 2023
PRE 14APreliminary proxy statement16 Oct 2023

Registrations(144)

S-8Registration statement (employee benefit plan)12 May
S-3Registration statement (primary offering)24 Mar
424B3Prospectus filing (Rule 424(b)(3))23 Apr 2025
S-3Registration statement (primary offering)15 Apr 2025
424B3Prospectus filing (Rule 424(b)(3))12 Sep 2024
S-8Registration statement (employee benefit plan)30 Aug 2024
S-3Registration statement (primary offering)30 Aug 2024
POS AMPost-effective amendment (unspecified)11 Apr 2024
POS AMPost-effective amendment (unspecified)11 Apr 2024
424B3Prospectus filing (Rule 424(b)(3))26 Feb 2024
424B3Prospectus filing (Rule 424(b)(3))26 Feb 2024
424B3Prospectus filing (Rule 424(b)(3))21 Feb 2024
424B3B24B321 Feb 2024
424B3Prospectus filing (Rule 424(b)(3))13 Feb 2024
424B4Prospectus filing (Rule 424(b)(4))9 Feb 2024

Filing Review Correspondence(21)

CORRESPFiling review correspondence31 Mar
CORRESPFiling review correspondence21 Apr 2025
CORRESPFiling review correspondence10 Sep 2024
CORRESPFiling review correspondence5 Feb 2024
CORRESPFiling review correspondence5 Feb 2024
CORRESPFiling review correspondence1 Feb 2024
CORRESPFiling review correspondence10 Aug 2023
CORRESPFiling review correspondence1 Feb 2023
CORRESPFiling review correspondence1 Jun 2022
CORRESPFiling review correspondence31 Aug 2021
CORRESPFiling review correspondence29 Sep 2020
CORRESPFiling review correspondence11 Sep 2020
CORRESPFiling review correspondence7 Dec 2018
CORRESPFiling review correspondence7 Dec 2018
CORRESPFiling review correspondence6 Dec 2018

SEC Orders And Notices(22)

EFFECTNotice of effectiveness2 Apr
EFFECTNotice of effectiveness23 Apr 2025
EFFECTNotice of effectiveness12 Sep 2024
EFFECTNotice of effectiveness12 Apr 2024
EFFECTNotice of effectiveness12 Apr 2024
EFFECTNotice of effectiveness7 Feb 2024
EFFECTNotice of effectiveness2 Feb 2023
EFFECTNotice of effectiveness3 Jun 2022
EFFECTNotice of effectiveness1 Sep 2021
EFFECTNotice of effectiveness30 Sep 2020
EFFECTNotice of effectiveness7 Dec 2018
EFFECTNotice of effectiveness23 May 2018
EFFECTNotice of effectiveness6 Mar 2015
EFFECTNotice of effectiveness8 Sep 2014
EFFECTNotice of effectiveness13 Jun 2014

Exempt Offerings(11)

D06b23 Aug 2024
D06b1 Jun 2022
D06b20 Jul 2021
D06b22 Jul 2020
D06b27 Mar 2020
D06b29 Nov 2013
DNotice of exempt offering of securities (Reg D)3 Sep 2013
DNotice of exempt offering of securities (Reg D)7 Aug 2013
DNotice of exempt offering of securities (Reg D)8 Mar 2013
DNotice of exempt offering of securities (Reg D)22 Jun 2009
DNotice of exempt offering of securities (Reg D)10 Jun 2009

Other(11)

SEC STAFF LETTERSEC STAFF LETTER29 Mar 2021
SEC STAFF LETTERSEC STAFF LETTER1 Mar 2021
CERTNASAUTO-GENERATED PAPER DOCUMENT13 Jan 2010
S-2S-215 Aug 2005
S-2S-214 Jan 2005
S-2S-22 Sep 2004
10-K405FORM 10-K FOR PERIOD ENDED 4/30/20003 Aug 2000
10-K40510-K4051 Sep 1999
10-K40510-K40529 Jul 1998
10-K40510-K40529 Jul 1997
10-K40510-K4052 Aug 1996